A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

NCT02586311 Phase 3 COMPLETED

Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 3
Status	COMPLETED
Enrolment	160
Start date	2016-01
Completion	2016-09

Conditions

• Hypertension

Interventions

• CKD-330 16/5mg
• Amlodipine 5mg Placebo
• CKD-330 16/5mg Placebo
• Amlodipine 5mg

Primary outcomes

• The mean change of sitSBP(sitting Systolic blood pressure) — From baseline at week 8

Countries

South Korea